New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

ROANOKE, Va. (WDBJ) - A Roanoke-based nonprofit founded in memory of a young woman diagnosed with a rare form of leukemia is marking seven years of service to young adults facing cancer treatment.

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

HealthDay News — In guidelines issued by the American Society of Hematology and published online February 11 in Blood Advances, recommendations are presented for frontline management of acute ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

While not every patient with AML develops skin involvement, it can be one of the earliest visible signs that something systemic is occurring.

Asciminib is the first-in-class allosteric inhibitor that specifically binds the BCR::ABL1 myristoyl pocket used to treat patients with Chronic Myeloid Leukemia (CML). The global incidence rate of CML ...

This is the first time that BXLS and Johnson & Johnson have entered into a co-funding agreement. "We believe that bleximenib's promising clinical data, combined with Johnson & Johnson's deep expertise ...